Question 1

Why is weight loss with semaglutide 2.4 mg lower in people with type 2 diabetes?

Accepted Answer

Mean weight loss in STEP-2 was 9.6% on semaglutide 2.4 mg, compared with 14.9% on the same dose in STEP-1 in non-diabetic adults. The gap is consistent across the GLP-1 literature: people with T2D lose roughly a third to a half less weight on incretin therapy than people without diabetes, even at identical doses. Hypothesized mechanisms include differences in incretin-receptor signaling in long-standing hyperglycemia, the energy-conserving effect of improved glucose disposal, concomitant antihyperglycemic medications, and a smaller baseline gap between intake and expenditure in the diabetic population. The effect is not erased by higher doses, but it is partially offset; the 2.4 mg dose still produced 2.7 percentage points more weight loss than the 1.0 mg dose in the same trial.

Question 2

Should a patient with type 2 diabetes use Wegovy (2.4 mg) or Ozempic (1.0 mg)?

Accepted Answer

STEP-2 is the closest the literature gets to a head-to-head answer. Both doses produced essentially identical HbA1c reductions of about 1.5-1.6 percentage points, so for glycemic control alone the 1.0 mg dose is sufficient. The 2.4 mg dose produced about 2.7 percentage points more weight loss and meaningfully higher rates of ≥10% and ≥15% weight reduction, at the cost of somewhat higher gastrointestinal AE rates and a higher discontinuation rate (6.7% vs 5.2%). The clinical decision usually turns on the patient's primary goal and insurance coverage: Ozempic is FDA-approved for diabetes and typically covered by commercial plans; Wegovy is FDA-approved for chronic weight management and historically faces more restrictive coverage even in patients with T2D.

Question 3

How does STEP-2 compare with SURMOUNT-2 (tirzepatide in T2D)?

Accepted Answer

SURMOUNT-2 (Garvey 2023, Lancet) was the analogous registrational trial for tirzepatide in adults with T2D and obesity, with a 72-week treatment period and 10 mg and 15 mg doses. Mean weight loss in SURMOUNT-2 was −13.4% on tirzepatide 10 mg and −15.7% on 15 mg, versus −3.3% on placebo. Direct cross-trial comparison should be made cautiously because protocols, populations, and durations differed, but the placebo-subtracted weight loss in the T2D population was roughly 6-10 percentage points larger for tirzepatide than for semaglutide 2.4 mg in STEP-2. HbA1c reductions were also larger with tirzepatide (about −2.0 percentage points on 15 mg vs −1.6 with sema 2.4 mg). SURMOUNT-2 supported the November 2024 FDA approval of Zepbound for T2D-associated weight management.

Question 4

Was hypoglycemia a problem in STEP-2?

Accepted Answer

Documented symptomatic hypoglycemia (blood glucose under 56 mg/dL) occurred in 5.7% of the semaglutide 2.4 mg arm versus 3.0% on placebo. Severe hypoglycemia was rare (0.7% on 2.4 mg vs 0.5% on placebo). The bulk of the excess was concentrated in participants taking background sulfonylureas, a known interaction; semaglutide itself is not insulinotropic in the absence of elevated glucose, so the hypoglycemia signal in the trial reflects sulfonylurea-driven insulin release in patients whose glucose was falling because of the GLP-1 effect. Practical implication is the same as for any GLP-1 in T2D: down-titrate or stop the sulfonylurea (and reduce insulin if present) when semaglutide is started.

Question 5

Did the HbA1c improvement persist through week 68?

Accepted Answer

Yes. HbA1c trajectories in the published figures show both active arms reaching nadir around weeks 20-28 and remaining at that nadir through week 68, with the 2.4 mg arm landing at −1.6 percentage points and the 1.0 mg arm at −1.5. By week 68, 67.5% of the 2.4 mg arm and 64.0% of the 1.0 mg arm reached HbA1c <7% (the ADA glycemic target), compared with 15.6% on placebo. The composite endpoint of ≥10% weight loss plus HbA1c <7% was achieved by 30.9% of the 2.4 mg arm vs 4.2% of placebo — the metabolic remission target that conventional T2D pharmacotherapy reaches in only a minority of patients.

Question 6

Did STEP-2 result in a specific FDA label change?

Accepted Answer

STEP-2 was one of the four pivotal trials in Novo Nordisk's June 2021 Biologics License Application for Wegovy, alongside STEP-1, STEP-3, and STEP-4. The FDA's initial Wegovy approval (June 4, 2021) covered chronic weight management in adults with BMI ≥30 or ≥27 with a weight-related comorbidity, with type 2 diabetes explicitly listed as one of the qualifying comorbidities. STEP-2 supplied the dedicated efficacy and safety dataset for the T2D-with-obesity subpopulation that allowed the label to extend uniformly into diabetic patients without a separate restriction. The trial did not change which dose is marketed for diabetes versus obesity; Ozempic (semaglutide 0.5-2.0 mg) remains the diabetes-labeled formulation and Wegovy (semaglutide 2.4 mg) the obesity-labeled one.

Endpoint	Treatment	Comparator	Difference
Percentage change in body weight at week 68, semaglutide 2.4 mg vs semaglutide 1.0 mg Direct head-to-head comparison of the obesity dose vs the Ozempic dose in T2D; the 2.4 mg arm produced an additional ~2.7 percentage points of weight loss over the 1.0 mg arm at the same 68-week endpoint.	−9.6% (2.4 mg)	−7.0% (1.0 mg)	Estimated treatment difference −2.7 percentage points (95% CI −3.7 to −1.6; P<0.0001)
Body-weight reduction ≥5% at week 68	68.8% (2.4 mg); 57.1% (1.0 mg)	28.5% (placebo)	Odds ratio 4.88 (95% CI 3.58 to 6.64) for 2.4 mg vs placebo; P<0.0001
Body-weight reduction ≥10% at week 68 More than five-fold higher absolute rate of clinically meaningful weight loss versus placebo in a population where most prior obesity drugs barely separated from placebo.	45.6% (2.4 mg); 28.7% (1.0 mg)	8.2% (placebo)	Odds ratio 7.41 (95% CI 4.95 to 11.08) for 2.4 mg vs placebo; P<0.0001
Body-weight reduction ≥15% at week 68	25.8% (2.4 mg); 13.7% (1.0 mg)	3.2% (placebo)	Odds ratio 7.65 (95% CI 4.44 to 13.20) for 2.4 mg vs placebo; P<0.0001
Change in HbA1c at week 68 (percentage points) Glycemic effect of the two doses was essentially identical, suggesting the HbA1c benefit plateaus near the 1.0 mg dose while weight-loss benefit continues to scale.	−1.6 (2.4 mg); −1.5 (1.0 mg)	−0.4 (placebo)	Estimated treatment difference −1.2 percentage points (95% CI −1.4 to −1.1) for 2.4 mg vs placebo; P<0.0001
Change in waist circumference at week 68 (cm)	−9.4 cm (2.4 mg)	−4.5 cm (placebo)	Estimated treatment difference −4.9 cm (95% CI −5.9 to −4.0); P<0.0001
Change in systolic blood pressure at week 68 (mmHg)	−3.9 mmHg (2.4 mg)	−0.5 mmHg (placebo)	Estimated treatment difference −3.4 mmHg (95% CI −5.6 to −1.3); P=0.0016
Change in fasting plasma glucose at week 68 (mg/dL)	−43.8 mg/dL (2.4 mg)	−8.5 mg/dL (placebo)	Estimated treatment difference approximately −35 mg/dL (95% CI −41 to −29); P<0.0001
Change in IWQOL-Lite-CT Physical Function score at week 68 Patient-reported physical function on the weight-specific IWQOL-Lite-CT instrument; the difference cleared the 14.6-point responder threshold for the 2.4 mg arm.	+14.1 points (2.4 mg)	+8.7 points (placebo)	Estimated treatment difference 5.3 points (95% CI 2.8 to 7.9); P<0.0001
Triglycerides (ratio to baseline) at week 68	0.78 (2.4 mg; 22% relative reduction)	0.93 (placebo; 7% relative reduction)	Estimated treatment ratio 0.84 (95% CI 0.79 to 0.89); P<0.0001

Event	Treatment rate	Comparator rate
Nausea Most common AE; rates with the 1.0 mg dose were 25.6%. Typically mild-to-moderate and clustered during dose-escalation.	33.7% (sema 2.4 mg)	11.4% (placebo)
Diarrhea Rate with the 1.0 mg dose was 19.0%.	21.5% (sema 2.4 mg)	7.4% (placebo)
Vomiting Rate with the 1.0 mg dose was 12.4%.	20.9% (sema 2.4 mg)	5.4% (placebo)
Constipation	17.8% (sema 2.4 mg)	8.2% (placebo)
Dyspepsia	8.7% (sema 2.4 mg)	1.7% (placebo)
Documented symptomatic hypoglycemia (BG <56 mg/dL) Severe hypoglycemia was rare in all arms (0.7% on 2.4 mg vs 0.5% on placebo). The hypoglycemia signal was concentrated in participants on background sulfonylureas, consistent with the established risk of combining incretin therapy with insulin secretagogues.	5.7% (sema 2.4 mg)	3.0% (placebo)
Diabetic retinopathy (any event) Numerically higher than placebo but not significant; consistent with the early-treatment retinopathy signal seen in other semaglutide diabetes trials when glucose drops rapidly.	3.2% (sema 2.4 mg)	2.7% (placebo)
Cholelithiasis (gallstones) Known class effect of rapid weight loss.	2.5% (sema 2.4 mg)	0.5% (placebo)
Discontinuation due to adverse events Driven predominantly by gastrointestinal events during dose-escalation; rate with the 1.0 mg dose was 5.2%.	6.7% (sema 2.4 mg)	3.5% (placebo)
Serious adverse events (any)	9.1% (sema 2.4 mg)	7.9% (placebo)

STEP-2 trial deep-dive: semaglutide 2.4 mg in obesity + type 2 diabetes (Davies 2021 Lancet)

Primary endpoint

Secondary endpoints

Adverse events

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives